AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY
*Complications could include high blood pressure, prediabetes, type 2 diabetes, heart disease, nonalchoholic fatty liver disease, osteoarthritis, and more. | https://www.aace.com/patient-journey/obesity
GLP-1S AND PREVENTING CVD Recent clinical trial data indicates that one of the GLP-1 receptor agonist medications used for diabetes and obesity treatment also slashes the risk of heart attacks and other cardiovascular incidents. 102 Researchers say the findings, if confirmed, could change the practice of preventive cardiology. An August 2023 article in Nature and Biotechnology Community News 103 says that researchers expected the particular drug used in the cited clin- ical trial to protect against heart disease because obesity is an important risk factor for CVD, and weight loss can lead to improvements in other risk factors such as blood pressure and cholesterol levels. But there’s also evidence that this class of drugs can improve fatty-acid metabolism and reduce inflammation.
102 https://www.nature.com/articles/d41586-023-02528-2 103 https://biotechnologycommunity.com/md_news/heart-disease-is-also-prevented-by-an-anti-obesity-medication/
32
Made with FlippingBook Online newsletter maker